MX9800358A - Formulacion farmaceutica estabilizada que comprende una hormona del crecimiento pretratada con zinc y opcionalmente lisina o iones calcio. - Google Patents

Formulacion farmaceutica estabilizada que comprende una hormona del crecimiento pretratada con zinc y opcionalmente lisina o iones calcio.

Info

Publication number
MX9800358A
MX9800358A MX9800358A MX9800358A MX9800358A MX 9800358 A MX9800358 A MX 9800358A MX 9800358 A MX9800358 A MX 9800358A MX 9800358 A MX9800358 A MX 9800358A MX 9800358 A MX9800358 A MX 9800358A
Authority
MX
Mexico
Prior art keywords
zinc
treated
growth hormone
calcium ions
pharmaceutical formulation
Prior art date
Application number
MX9800358A
Other languages
English (en)
Other versions
MXPA98000358A (es
Inventor
Thorkild Christensen
Per Balschmidt
Hans Holmegaard Soerensen
Ole Hvilsted Olsen
Lars Thim
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX9800358A publication Critical patent/MX9800358A/es
Publication of MXPA98000358A publication Critical patent/MXPA98000358A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona una formulacion farmacéutica que comprende una hormona del crecimiento pretratada con zinc y opcionalmente lisina o iones calcio que muestra una estabilidad muy elevada durante la desaminacion, oxidacion y ruptura de enlaces peptídicos. La estabilidad del producto permite el almacenamiento y envío del mismo en un estado liofilizado o en forma de una formulacion disuelta o redisuelta a temperatura ambiente.
MXPA/A/1998/000358A 1995-07-14 1998-01-12 Formulacion farmaceutica estabilizada que comprende una hormona del crecimiento pretratada con zincy opcionalmente lisina o iones calcio MXPA98000358A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US119395P 1995-07-14 1995-07-14
US001193 1995-07-14
PCT/DK1996/000293 WO1997003692A1 (en) 1995-07-14 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions

Publications (2)

Publication Number Publication Date
MX9800358A true MX9800358A (es) 1998-07-31
MXPA98000358A MXPA98000358A (es) 1998-11-09

Family

ID=

Also Published As

Publication number Publication date
NO980155D0 (no) 1998-01-13
KR19990028981A (ko) 1999-04-15
AU715997B2 (en) 2000-02-17
CA2226523A1 (en) 1997-02-06
HUP9802287A3 (en) 2000-10-30
ZA965368B (en) 1997-01-14
EP0839049A1 (en) 1998-05-06
HUP9802287A2 (hu) 1999-02-01
AU6353496A (en) 1997-02-18
JPH11509212A (ja) 1999-08-17
NO980155L (no) 1998-01-13
PL324379A1 (en) 1998-05-25
CZ9498A3 (cs) 1998-06-17
BR9609741A (pt) 1999-03-16
CN1190897A (zh) 1998-08-19
WO1997003692A1 (en) 1997-02-06
IL122583A0 (en) 1998-06-15

Similar Documents

Publication Publication Date Title
NO980155L (no) Stabilisert farmasöytisk preparat som omfatter et veksthormon som er forbehandlet med sink og eventuelt lysin eller kasiumioner
HU9401831D0 (en) Stabilized pharmaceutical formulations comprising growth hormone and asparagine
IL115590A (en) Pharmaceutical formulation comprising a growth hormone and isoleucine
AU610636B2 (en) Stabilised human protein preparations
AU587432B2 (en) Drug depot containing cytostatics
CA2149925A1 (fr) Derives peptidiques de l'.alpha.-msh et leur application
IL115591A0 (en) Pharmaceutical formulation comprising a growth hormone and valine
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
HK1045652A1 (zh) 長期穩定的製劑
EP0643963A3 (en) Bioerodible device for the administration of active agents.
CA2155005A1 (en) Pharmaceutical Compositions Containing Bactericidal Permeability Increasing Protein and a Surfactant
AU1111695A (en) Composition for the production of therapeutic products in vivo
EP1308170A3 (en) Dried blood factor composition comprising trehalose
NZ320237A (en) Stable pharmaceutical forms of administration containing parathormone
EP0791601A3 (en) An agent promoting bone formation and inhibiting bone resorption
AU2670495A (en) Ifn-beta liquid formulations
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
MX9800309A (es) Formulacion farmaceutica estabilizada que comprende una hormona del crecimiento y un peptido que comprende al menos un residuo de aminoacido basico y al menos un residuo de aminoacido acido.
ZA9710254B (en) LH-RH peptide analogues, their uses and pharmaceutical composition containing them.
ATE216586T1 (de) Hirudin enthaltende arzneimittel
AU1879097A (en) Fragments of cr1 and their use
AU5497698A (en) Method for stabilizing peptide and peptide-containing lyophilized pharmaceutical composition using the method
MX9705667A (es) Derivados de insulina con union a zinc incrementada.